Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KODNASDAQ:ORPHNASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKODKodiak Sciences$3.57+2.0%$3.31$1.92▼$11.60$188.37M2.42345,668 shs180,763 shsORPHOrphazyme A/S$1.43$0.51▼$77.77$30.72M1.681.37 million shs941,400 shsPHARPharming Group$10.60+5.8%$8.91$6.65▼$11.07$721.13M-0.086,447 shs907 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKODKodiak Sciences+2.00%+0.56%-14.18%-13.14%+21.02%ORPHOrphazyme A/S0.00%0.00%0.00%0.00%0.00%PHARPharming Group+3.11%+0.95%+20.66%+21.63%+14.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKODKodiak Sciences4.1296 of 5 stars3.03.00.04.61.93.30.6ORPHOrphazyme A/SN/AN/AN/AN/AN/AN/AN/AN/APHARPharming Group2.5611 of 5 stars3.55.00.00.02.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKODKodiak Sciences 2.00Hold$9.00152.10% UpsideORPHOrphazyme A/S 0.00N/AN/AN/APHARPharming Group 3.00Buy$30.00183.02% UpsideCurrent Analyst Ratings BreakdownLatest PHE, PHAR, KOD, and ORPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025KODKodiak SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.003/20/2025PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00 ➝ $37.003/14/2025PHARPharming GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$30.00 ➝ $39.003/14/2025PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00 ➝ $37.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKODKodiak SciencesN/AN/AN/AN/A$5.07 per shareN/AORPHOrphazyme A/SN/AN/AN/AN/A$2.74 per shareN/APHARPharming Group$320.71M2.25$0.12 per share91.82$3.26 per share3.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKODKodiak Sciences-$260.49M-$3.63N/AN/AN/AN/A-84.52%-45.40%8/13/2025 (Estimated)ORPHOrphazyme A/S-$97.01MN/A0.00N/AN/AN/AN/AN/AN/APHARPharming Group-$10.55M-$0.20N/A353.33N/A-6.09%-7.65%-3.82%7/30/2025 (Estimated)Latest PHE, PHAR, KOD, and ORPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/A5/8/2025Q1 2025PHARPharming Group-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 million3/27/2025Q4 2024KODKodiak Sciences-$0.90-$0.84+$0.06-$0.84N/AN/A3/13/2025Q4 2024PHARPharming Group$0.07$0.05-$0.02$0.05$76.67 million$92.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKODKodiak SciencesN/AN/AN/AN/AN/AORPHOrphazyme A/SN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKODKodiak SciencesN/A8.428.42ORPHOrphazyme A/S0.141.80N/APHARPharming Group0.413.532.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKODKodiak Sciences89.06%ORPHOrphazyme A/S10.74%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipKODKodiak Sciences45.30%ORPHOrphazyme A/SN/APHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKODKodiak Sciences9052.76 million28.79 millionOptionableORPHOrphazyme A/S14135.31 millionN/ANot OptionablePHARPharming Group28068.03 million66.62 millionNot OptionablePHE, PHAR, KOD, and ORPH HeadlinesRecent News About These CompaniesPharming Group (NASDAQ:PHAR) Shares Gap Down - Should You Sell?May 29 at 12:08 PM | marketbeat.comPharming Group to participate in June investor conferencesMay 28 at 4:26 AM | finance.yahoo.comPharming Group to participate in June investor conferences | PHARM Stock NewsMay 28 at 2:16 AM | gurufocus.comQ2 EPS Estimates for Pharming Group Decreased by AnalystMay 13, 2025 | marketbeat.comPharming Group First Quarter 2025 Earnings: US$0.022 loss per share (vs US$0.019 loss in 1Q 2024)May 10, 2025 | finance.yahoo.comPharming Group N.V. (PHAR) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comPharming Group N.V. 2025 Q1 - Results - Earnings Call PresentationMay 9, 2025 | seekingalpha.comPharming Group’s Strong Financial Performance and Strategic Growth Drive Buy RatingMay 8, 2025 | tipranks.comPharming Group N.V.: Pharming Group reports first quarter 2025 financial results and provides business updateMay 8, 2025 | finanznachrichten.dePharming Group reports first quarter 2025 financial results and provides business updateMay 8, 2025 | taiwannews.com.twPharming Group reports first quarter 2025 financial results and provides business update | ...May 8, 2025 | gurufocus.comEarnings To Watch: Pharming Group (PHGUF) Reports Q1 2025 ResultMay 7, 2025 | gurufocus.comPharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive DirectorApril 30, 2025 | finance.yahoo.comPharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume - What's Next?April 30, 2025 | marketbeat.comPharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of ...April 30, 2025 | gurufocus.comShort Interest in Pharming Group (NASDAQ:PHAR) Declines By 36.0%April 30, 2025 | marketbeat.comPharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical ...April 25, 2025 | gurufocus.comPharming Group to Present Key Findings at Clinical Immunology Society MeetingApril 25, 2025 | tipranks.comPharming receives positive recommendation from NICE for Joenja®?(leniolisib) as a treatment for APDSApril 24, 2025 | tmcnet.comPharming receives positive recommendation from NICE for Joenja to treat APDS in adult and paediatric patients 12 years of age and olderApril 24, 2025 | pharmabiz.comPharming Group to report first quarter 2025 financial results on May 8 | PHARM Stock NewsApril 24, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsThese Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioBy Leo Miller | May 22, 2025View These Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioPharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t IgnoreBy Sam Quirke | May 14, 2025View Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t IgnoreEli Lilly : A Breakout Biotech Powerhouse With Room to RunBy Jeffrey Neal Johnson | May 29, 2025View Eli Lilly : A Breakout Biotech Powerhouse With Room to RunIs Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?By Leo Miller | May 6, 2025View Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?PHE, PHAR, KOD, and ORPH Company DescriptionsKodiak Sciences NASDAQ:KOD$3.57 +0.07 (+2.00%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$3.54 -0.03 (-0.84%) As of 05/29/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Orphazyme A/S NASDAQ:ORPHOrphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.Pharming Group NASDAQ:PHAR$10.60 +0.58 (+5.79%) Closing price 05/29/2025 03:55 PM EasternExtended Trading$10.28 -0.32 (-3.07%) As of 05/29/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
